Inventor · disambiguated record
Christiane Stadler
Also filed as: STADLER CHRISTIANE · STADLER CHRISTIANE REGINA
7 granted patents·9 pending applications·26 citations·filing 2013–2024
83Inventor score
Top patents by PatentIndex Score
16 records- 0191US10813996B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2018·Granted Oct 27, 2020·4 cites·18 claims
- 0290US10717780B2Agents for treatment of claudin expressing cancer diseasesBIONTECH AG·Filed 2018·Granted Jul 21, 2020·5 cites·12 claims
- 0385US11787862B2Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseasesBIONTECH AG·Filed 2017·Granted Oct 17, 2023·3 cites·32 claims
- 0485US2024335533A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerASTELLAS PHARMA INC·Filed 2024·Application pending·0 cites
- 0584US10093736B2Agents for treatment of claudin expressing cancer diseasesBIONTECH AG·Filed 2013·Granted Oct 9, 2018·7 cites·9 claims
- 0683US9433675B2Combination therapy involving antibodies against claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2013·Granted Sep 6, 2016·5 cites·23 claims
- 0779US10022444B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Jul 17, 2018·2 cites·32 claims
- 0874US2024228616A1Agents for Treatment of Claudin Expressing Cancer DiseasesBIONTECH AG·Filed 2022·Application pending·0 cites
- 0972US12059464B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerASTELLAS PHARMA INC·Filed 2020·Granted Aug 13, 2024·0 cites·22 claims
- 1070US2024158501A1Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseasesBioNTech SE·Filed 2023·Application pending·0 cites
- 1165US2020399370A1Agents for Treatment of Claudin Expressing Cancer DiseasesBIONTECH AG·Filed 2020·Application pending·0 cites
- 1254US2025009780A1Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancersBioNTech SE·Filed 2022·Application pending·0 cites
- 1351US2024043527A1Rna compositions targeting claudin-18.2BioNTech SE·Filed 2021·Application pending·0 cites
- 1449US2015132253A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2013·Application pending·0 cites
- 1548US2023287088A1Binding agents for coronavirus s proteinBioNTech SE·Filed 2021·Application pending·0 cites
- 1648US2018258180A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →